Allergic Bronchopulmonary Aspergillosis Panel II

Last Modified: 12/29/2022 8:22:53 AM


  Medicare Medical Necessity Restrictions May Apply
Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements: 1.5 mL Serum from a SST Gold Top Tube
Collection Instructions:  
Transport & Storage: Temperature/Stability: 4 weeks Ambient
4 weeks Refrigerated
4 weeks Frozen
Reference Range: Refer to Interpretive Results
Critical Ranges:  
Test Comments:  
Methodology: Multiple
Clinical Significance: ABPA is a hypersensitivity disease of the lungs caused by Aspergillus fumigatus. It is an important complication for patients with asthma and cystic fibrosis. Diagnosis involves clinical, immunologic and radiographic criteria and no single test is sufficiently discriminating. ABPA is under-diagnosed: prospective studies indicate that 7 to 14 % of patients with corticosteroid-dependent asthma meet the generally accepted definitions as to 6% of patients with cystic fibrosis. Individuals with the HLA DR2 and HLA DR5 haplotypes appear to be predisposed to ABPA.
Documentation:  
Custom Panel: No

PRODUCTION SCHEDULE

Sites Performed: Eurofins (Previously Viracor)
PHL Test Code: MSOT
EPIC Test Code:
Send Out Test Code: 403016P
Alternate Test Names: ABPA; ABPA Panel II; Allergic Broncopulmonary Aspergillosis Panel II ; Ouchterlony
Included Tests:

Aspergillus fumigatus IgE; Aspergillus fumigatus IgG; Aspergillus fumigatus Mix Gel Diffusion; Total IgE
CPT Coding: 82785, 86001, 86003, 86331

Go back to the top of the page.